North America Clinical Trials Market Report by Phases, Indications, Study Designs, Countries and Companies Analysis 2026-2034

North America Clinical Trials Market is anticipated to witness substantial growth, expanding from US$ 21.27 Billion in 2025 to US$ 35.94 Billion by 2034. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 6.00% during the forecast period of 2026-2034. Market expansion is driven by increasing investments in pharmaceutical and biotechnology research, rising demand for innovative therapies, advancements in clinical trial technologies, and a supportive regulatory environment across the region.

North America Clinical Trials Industry Overview

Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy, and potential side effects of new drugs, medical devices, vaccines, and treatment procedures before they receive regulatory approval. These trials are typically carried out in multiple phases, ranging from initial safety assessments to large-scale studies that confirm therapeutic benefits. Clinical trials play a critical role in advancing medical science and ensuring that healthcare innovations meet established quality and safety standards.

Clinical trials have gained significant popularity in North America due to the region’s advanced healthcare infrastructure, strong pharmaceutical and biotechnology sectors, and substantial investment in research and development activities. The presence of leading academic institutions, contract research organizations (CROs), and globally recognized pharmaceutical companies further strengthens the clinical trial ecosystem. Additionally, supportive regulatory frameworks, increasing prevalence of chronic diseases, and growing demand for personalized medicine have accelerated the number of clinical studies conducted across the region. The widespread adoption of digital health technologies and decentralized trial models has also improved patient recruitment, engagement, and data collection, enhancing the overall efficiency of clinical research in North America.

Top 10 companies by number of clinical trials in North America in 2025

Rank Company Estimated Active Clinical Trials Key Therapeutic Areas

• AstraZeneca ~160+ Oncology, Respiratory, Cardiovascular
• Eli Lilly and Company ~140+ Diabetes, Obesity, Oncology
• Pfizer Inc. ~130+ Vaccines, Oncology, Rare Diseases
• Merck & Co. ~120+ Oncology, Infectious Diseases
• Novartis AG ~110+ Oncology, Cardiovascular, Gene Therapy
• Roche Holding AG ~100+ Oncology, Neurology, Diagnostics
• Johnson & Johnson ~90+ Immunology, Oncology, Neuroscience
• Bristol Myers Squibb ~85+ Oncology, Hematology, Immunology
• Amgen Inc. ~75+ Oncology, Cardiovascular, Inflammation
• AbbVie Inc. ~70+ Immunology, Oncology, Neuroscience

Sources: Pharma Board

Recent Developments

• The latest FDA approval encompasses Linvoseltamab-gcpt (Lynozyfic), a bispecific antibody for relapsed or refractory multiple myeloma, received in July 2025. Also, Amgen and Kyowa Kirin explored a Phase 3 study of rocatilimab in September 2025, a treatment for adults with moderate-to-severe atopic dermatitis.
• In April 2025, Janssen Pharmaceuticals received FDA approval for this monoclonal antibody used for treating generalized myasthenia gravis, a rare neuromuscular disorder.
• In August 2025, THL Partners, a premier private equity firm, entered into a definitive agreement to acquire Headlands Research, a leading multinational network of clinical trial sites, to advance site network expansion and escalate clinical trial innovation.
• In July 2025, Biogen Inc. invested $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP) to continue breakthroughs of Biogen’s late-stage clinical pipeline.
• In February 2025, Tasso Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, and ARUP Laboratories, the largest nonprofit clinical and academic reference laboratory in the United States, partnered to establish and operationalize high-quality, at-home blood testing services to support clinical research.
• In May 2025, IQVIA announced to introduce a site lab navigator to optimize clinical trial workflows. This innovative suite of solutions is designed to automate and optimize laboratory workflows for both clinical trial sponsors and investigator sites.
• In April 2025, Thermo Fisher Scientific Inc. announced to use advanced platform technology along with a new CHO K-1 cell line, which can shorten the timeline for Investigational New Drug (IND) filings from 13 months to nine months. This innovation assists biotech and pharmaceutical companies in navigating the logistical challenges associated with pre-clinical biologic drug development.
• In January 2025, ICON plc announced the enhancement of its range of artificial intelligence (AI) tools, which aim to improve efficiency throughout the clinical trial process. This includes areas such as study initiation, document handling, resource forecasting, and reporting of metrics.
• In September 2025, Armida Labs, Inc., a University of California, Riverside startup company awarded a $2.25 million Small Business Innovation Research, or SBIR, grant from the National Cancer Institute of the National Institutes of Health, to support preclinical investigational new drug (IND) application studies.
• In September 2025, Crystalys Therapeutics emerged from stealth mode with a funding round of $205 million to assist in financing global late-stage trials of its lead drug as a treatment for gout.
• In September 2025, City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S., introduced a groundbreaking national clinical trials model to enhance access to developing life-saving cancer treatments.
• In January 2025, California vaccine company Arcturus Therapeutics unveiled a Phase I trial of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate created to combat the H5N1 virus, known as bird flu.

In September 2025, Imlunestrant was approved by the FDA for advanced or metastatic ER-positive, HER2-negative breast cancer with an ESR1 mutation that has grown after other endocrine therapy. Additionally, the Canadian BR38 trial integrated radiotherapy with immunotherapy for metastatic NSCLC with restricted growth.

Growth Drivers for the North America Clinical Trials Market

Growing Burden of Long-Term Health Conditions

The increasing occurrence of chronic health disorders across North America is a major catalyst for the clinical trials market. Conditions such as cancer, heart disease, obesity, and diabetes continue to affect a large portion of the population, creating a strong demand for innovative treatment solutions. Pharmaceutical manufacturers, biotechnology firms, and research organizations are investing heavily in clinical studies to develop safer and more effective therapies. Since many chronic diseases require continuous care and long-term treatment strategies, extensive clinical testing is necessary to validate new medical interventions. Furthermore, the region’s aging population is contributing to a higher prevalence of these conditions, encouraging sustained research efforts and expanding the need for clinical trial activities.

Rapid Integration of Advanced Digital Technologies

The adoption of cutting-edge technologies is transforming the way clinical trials are conducted throughout North America. Innovations such as artificial intelligence, predictive analytics, machine learning, cloud computing, and real-world data platforms are streamlining various stages of the clinical research process. These tools improve patient recruitment, enhance data accuracy, accelerate analysis, and support more informed decision-making. Digital solutions also enable remote patient monitoring and decentralized trial models, reducing operational inefficiencies and improving participant engagement. As a result, sponsors can conduct studies more efficiently, shorten development timelines, and increase the likelihood of successful outcomes, making technology a key driver of market growth.

Expanding Focus on Cancer Drug Development

The rising prevalence of cancer and the ongoing search for advanced treatment options have significantly increased investment in oncology-focused research across North America. Government agencies, private investors, academic institutions, and pharmaceutical companies are allocating substantial resources toward the development of next-generation cancer therapies. This has led to a surge in clinical studies evaluating immunotherapies, precision medicines, cell and gene therapies, and targeted treatment approaches. Strong collaboration between research centers and industry participants has accelerated trial initiation and patient enrollment. With cancer remaining a leading public health concern, oncology continues to represent one of the most active and rapidly expanding segments within the regional clinical trials market.

Challenges in the North America Clinical Trials Market

Escalating Costs of Clinical Research Operations

Managing clinical trials in North America involves considerable financial investment, making cost management a persistent challenge for market participants. Expenses associated with investigator fees, site management, patient recruitment, regulatory compliance, data management systems, and advanced technologies can substantially increase overall trial budgets. Complex study protocols, longer follow-up periods, and multi-center trial structures further add to operational expenditures. Smaller biotechnology companies and independent research organizations often face financial constraints that limit their ability to conduct large-scale studies without external funding or strategic partnerships. As clinical trials become increasingly sophisticated and personalized, maintaining cost efficiency while ensuring high-quality outcomes remains a significant industry challenge.

Stringent and Evolving Regulatory Requirements

The highly regulated nature of the clinical research industry presents another major obstacle for stakeholders operating in North America. Regulatory authorities impose rigorous standards to ensure participant safety, data integrity, and treatment effectiveness. Navigating these requirements often involves extensive documentation, ethics committee approvals, protocol reviews, and continuous compliance monitoring. Frequent updates to regulatory guidelines can further complicate trial planning and execution. Additionally, studies conducted across multiple sites or countries must address varying regulatory expectations, increasing administrative complexity. These challenges can prolong approval timelines, delay patient enrollment, and increase operational burdens, ultimately impacting the speed and efficiency of clinical development programs.

United States Clinical Trials Market

The United States represents the largest and most influential clinical trials market in North America, supported by advanced healthcare infrastructure, world-class research institutions, and significant investments in pharmaceutical and biotechnology innovation. The country hosts numerous drug developers, academic medical centers, and contract research organizations that conduct studies across a wide range of therapeutic areas. Strong support from regulatory and funding bodies encourages continuous clinical research and accelerates the development of new therapies. The increasing use of digital technologies, artificial intelligence, and decentralized trial models is improving patient recruitment, monitoring, and data management. Market growth is also driven by high healthcare expenditure and the growing burden of chronic and infectious diseases. The presence of major CROs, including Charles River Laboratories, IQVIA, Parexel, ICON plc, and Syneos Health, further strengthens the research ecosystem. Despite its leadership position, the market faces challenges related to rising trial costs, regulatory complexity, and the need to improve diversity and representation among clinical trial participants. In May 2025, the US-based START Center for Cancer Research (START) and OneOncology allied to unveil three early-phase trial sites in the US.

Canada Clinical Trials Market

Canada has established itself as a prominent destination for clinical research due to its strong healthcare system, skilled workforce, and favorable regulatory framework. The country offers an efficient environment for conducting clinical studies, supported by well-developed research institutions, leading universities, and specialized healthcare centers. Clinical trials in Canada cover various therapeutic areas, including oncology, neurology, infectious diseases, and rare disorders. Streamlined ethics review processes and transparent regulatory requirements help attract both domestic and international sponsors. Government initiatives, research grants, and collaborations between academic institutions and industry players continue to support innovation in clinical development. Additionally, Canada’s diverse population provides opportunities for broad patient participation and high-quality data collection. However, the market faces challenges such as competition from other global research destinations, participant recruitment limitations, and the need to increase diversity across trial populations. Addressing these issues will be important for maintaining Canada’s competitiveness and strengthening its role in global clinical research. In May 2025, AbCellera received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L)

Mexico Clinical Trials Market

Mexico is emerging as an attractive hub for clinical trials due to its cost advantages, expanding healthcare capabilities, and improving regulatory landscape. The country offers lower operational expenses compared to many developed markets, making it an appealing location for pharmaceutical companies seeking efficient research solutions. Its geographical proximity to the United States further enhances its strategic importance for multinational clinical studies. Regulatory reforms implemented by health authorities have streamlined approval procedures and reduced study start-up timelines, encouraging greater participation from international sponsors. Mexico also benefits from a large and diverse patient population, which supports faster participant enrollment and improved study outcomes. The growing adoption of digital health platforms, remote monitoring technologies, and decentralized clinical trial models is further enhancing research efficiency. Despite these strengths, challenges related to infrastructure disparities and patient awareness remain. Nevertheless, continued regulatory improvements and increasing investment are expected to strengthen Mexico’s position within the North American clinical trials market.

Market Segments

Phases

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Indications

• Autoimmune/Inflammation
• Pain management
• Oncology
• CNS Condition
• Diabetes
• Obesity
• Cardiovascular
• Others

Study Designs

• Interventional
• Observational
• Expanded Access

Countries

• United States
• Canada
• Mexico
• Rest of North America

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• ICON Plc
• Wuxi AppTec
• SGS SA
• Syneos Health
• PRA Health Sciences Inc
• Pfizer Inc.
• IQVIA
• Medpace